Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

Benzinga Newsdesk www.benzinga.com Positive 91.0%

Neg 0% Neu 0% Pos 91%

Citizens analyst Jonathan Wolleben upgrades Quince Therapeutics (NASDAQ:QNCX) from Market Perform to Market Outperform and announces $77 price target.